KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gains from Sales and Divestitures (2016 - 2017)

Historic Gains from Sales and Divestitures for Biomarin Pharmaceutical (BMRN) over the last 7 years, with Q4 2017 value amounting to $837926.0.

  • Biomarin Pharmaceutical's Gains from Sales and Divestitures rose 1154.45% to $837926.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $837926.0, marking a year-over-year increase of 1154.45%. This contributed to the annual value of $837926.0 for FY2017, which is 1154.45% up from last year.
  • According to the latest figures from Q4 2017, Biomarin Pharmaceutical's Gains from Sales and Divestitures is $837926.0, which was up 1154.45% from $751203.0 recorded in Q4 2016.
  • Over the past 5 years, Biomarin Pharmaceutical's Gains from Sales and Divestitures peaked at $837926.0 during Q4 2017, and registered a low of $300968.0 during Q4 2013.
  • Its 5-year average for Gains from Sales and Divestitures is $552546.0, with a median of $489301.0 in 2015.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Gains from Sales and Divestitures surged by 5352.57% in 2016, and later surged by 1154.45% in 2017.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Gains from Sales and Divestitures stood at $300968.0 in 2013, then rose by 27.37% to $383332.0 in 2014, then rose by 27.64% to $489301.0 in 2015, then skyrocketed by 53.53% to $751203.0 in 2016, then increased by 11.54% to $837926.0 in 2017.
  • Its last three reported values are $837926.0 in Q4 2017, $751203.0 for Q4 2016, and $489301.0 during Q4 2015.